News
A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...
The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...
An AI test boosts cure chances for prostate cancer by predicting who benefits from abiraterone, reducing side effects and ...
Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...
Dr. Cheryl Matter shares expert insights into the role physician education can play in ensuring innovative tools reach patients and help improve patient care.
In this pilot trial, acupuncture produced greater reductions in nocturia (waking up 1 or more times to urinate) relative to ...
Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback